587 related articles for article (PubMed ID: 16752313)
21. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency.
Carbonaro DA; Jin X; Petersen D; Wang X; Dorey F; Kil KS; Aldrich M; Blackburn MR; Kellems RE; Kohn DB
Mol Ther; 2006 Jun; 13(6):1110-20. PubMed ID: 16651028
[TBL] [Abstract][Full Text] [Related]
22. Amendment to Clinical Research Project. Project 90-C-195. April 1, 1993. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene.
Dunbar C; Chang L; Mullen C; Ramsey WJ; Carter C; Kohn D; Parkman R; Lenarsky C; Weinberg K; Wara D; Culver KW; Anderson WF; Leitman S; Fleisher T; Klein H; Shearer G; Clerici M; McGarrity G; Bastian J; Hershfield MS
Hum Gene Ther; 1999 Feb; 10(3):477-88. PubMed ID: 10048399
[No Abstract] [Full Text] [Related]
23. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
[TBL] [Abstract][Full Text] [Related]
24. Primary immunodeficiencies: molecular aspects and treatment.
Fischer A
Bone Marrow Transplant; 1992; 9 Suppl 1():39-43. PubMed ID: 1354525
[No Abstract] [Full Text] [Related]
25. Visible integration of the adenosine deaminase (ADA) gene into the recipient genome after gene therapy.
Egashira M; Ariga T; Kawamura N; Miyoshi O; Niikawa N; Sakiyama Y
Am J Med Genet; 1998 Jan; 75(3):314-7. PubMed ID: 9475605
[TBL] [Abstract][Full Text] [Related]
26. Gene therapy fulfilling its promise.
Kohn DB; Candotti F
N Engl J Med; 2009 Jan; 360(5):518-21. PubMed ID: 19179320
[No Abstract] [Full Text] [Related]
27. Gene transfer therapy for heritable disease: cell and expression targeting.
Mitani K; Clemens PR; Moseley AB; Caskey CT
Philos Trans R Soc Lond B Biol Sci; 1993 Feb; 339(1288):217-24. PubMed ID: 8097051
[TBL] [Abstract][Full Text] [Related]
28. Gene therapy for inherited immunodeficiencies.
Howe S; Thrasher AJ
Curr Hematol Rep; 2003 Jul; 2(4):328-34. PubMed ID: 12901330
[TBL] [Abstract][Full Text] [Related]
29. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM
Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239
[TBL] [Abstract][Full Text] [Related]
30. [Gene therapy for hereditary immunodeficiencies].
Fischer A; de Saint-Basile G; Disanto JP; Hacein-Bey S; Sharara L; Cavazzana-Calvo M
C R Seances Soc Biol Fil; 1996; 190(1):77-93. PubMed ID: 8881271
[TBL] [Abstract][Full Text] [Related]
31. Gene therapy for adenosine deaminase deficiency.
Aiuti A; Ficara F; Cattaneo F; Bordignon C; Roncarolo MG
Curr Opin Allergy Clin Immunol; 2003 Dec; 3(6):461-6. PubMed ID: 14612670
[TBL] [Abstract][Full Text] [Related]
32. Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID.
Aiuti A; Brigida I; Ferrua F; Cappelli B; Chiesa R; Marktel S; Roncarolo MG
Immunol Res; 2009; 44(1-3):150-9. PubMed ID: 19224139
[TBL] [Abstract][Full Text] [Related]
33. [The gene therapy for a patient with ADA deficiency; report of the first gene therapy trial in Japan].
Ariga T; Kawamura N; Sakiyama Y
Nihon Rinsho; 1997 Jun; 55(6):1572-9. PubMed ID: 9200950
[TBL] [Abstract][Full Text] [Related]
34. Gene therapy for primary adaptive immune deficiencies.
Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
J Allergy Clin Immunol; 2011 Jun; 127(6):1356-9. PubMed ID: 21624615
[TBL] [Abstract][Full Text] [Related]
35. Progress towards hematopoietic stem cell gene therapy.
Kurre P; Kiem HP
Curr Opin Mol Ther; 2000 Aug; 2(4):400-11. PubMed ID: 11249770
[TBL] [Abstract][Full Text] [Related]
36. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
Silver JN; Flotte TR
Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic stem cell gene therapy with drug resistance genes: an update.
Budak-Alpdogan T; Banerjee D; Bertino JR
Cancer Gene Ther; 2005 Nov; 12(11):849-63. PubMed ID: 16037821
[TBL] [Abstract][Full Text] [Related]
38. [Adenosine deaminase deficiency].
Okawa H
Ryoikibetsu Shokogun Shirizu; 1998; (21 Pt 2):240-2. PubMed ID: 9833480
[No Abstract] [Full Text] [Related]
39. Gene transfer of adenosine deaminase into primitive human hematopoietic progenitor cells.
Cournoyer D; Scarpa M; Mitani K; Moore KA; Markowitz D; Bank A; Belmont JW; Caskey CT
Hum Gene Ther; 1991; 2(3):203-13. PubMed ID: 1751590
[TBL] [Abstract][Full Text] [Related]
40. The importance of adenosine deaminase for lymphocyte development and function.
Aldrich MB; Blackburn MR; Kellems RE
Biochem Biophys Res Commun; 2000 Jun; 272(2):311-5. PubMed ID: 10833410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
